Research programme: brain disorders therapeutics - GlaxoSmithKline/BBB Therapeutics
Latest Information Update: 07 Oct 2014
At a glance
- Originator GlaxoSmithKline
- Developer BBB Therapeutics; GlaxoSmithKline
- Class Biological factors
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain disorders
Most Recent Events
- 07 Oct 2014 No development reported for Brain disorders in China (IV)
- 30 Sep 2014 to-BBB technologies is now called BBB Therapeutics